Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Late presentation of Torsades de Pointes related to fluoxetine following a multiple drug overdose.

Groot JAN, Ten Bokum L, van den Oever HLA.

J Intensive Care. 2018 Sep 10;6:59. doi: 10.1186/s40560-018-0329-1. eCollection 2018.

2.

[Periodic electrocardiographic monitoring of the QT interval in patients on SSRI treatment].

Muquebil Ali Al Shaban Rodríguez OW.

Semergen. 2018 Jul - Aug;44(5):e107-e108. doi: 10.1016/j.semerg.2018.03.004. Spanish. No abstract available.

PMID:
29759853
3.

Psychotropic Pharmacotherapy Associated With QT Prolongation Among Veterans With Posttraumatic Stress Disorder.

Stock EM, Zeber JE, McNeal CJ, Banchs JE, Copeland LA.

Ann Pharmacother. 2018 Sep;52(9):838-848. doi: 10.1177/1060028018769425. Epub 2018 Apr 11.

PMID:
29642718
5.

Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.

Khan Q, Ismail M, Haider I, Khan F.

Int J Clin Pharm. 2017 Dec;39(6):1256-1264. doi: 10.1007/s11096-017-0532-5. Epub 2017 Sep 12.

PMID:
28895028
6.

[Long QT syndrome due to Fluoxetine].

Canet Fajas C, Urieta González L, Ibañez Pérez de Viñaspre JA.

Semergen. 2018 Jan - Feb;44(1):66-68. doi: 10.1016/j.semerg.2017.06.006. Epub 2017 Aug 26. Spanish. No abstract available.

PMID:
28851566
7.

Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations.

Snitker S, Doerfler RM, Soliman EZ, Deo R, St Peter WL, Kramlik S, Fischer MJ, Navaneethan S, Delafontaine P, Jaar BG, Ojo A, Makos GK, Slaven A, Weir MR, Zhan M, Fink JC; for CRIC Study Investigators.

Clin J Am Soc Nephrol. 2017 Aug 9;12(9). pii: CJN.12991216. doi: 10.2215/CJN.12991216. Print 2017 Sep 7.

8.

A comparative study of QT prolongation with serotonin reuptake inhibitors.

Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, Montastruc F, Montastruc JL.

Psychopharmacology (Berl). 2017 Oct;234(20):3075-3081. doi: 10.1007/s00213-017-4685-7. Epub 2017 Aug 3.

PMID:
28770276
9.

Thioridazine Therapy and CYP2D6 Genotypes.

Dean L.

In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.
2017 Feb 9.

10.

A Pilot Study: Cardiac Parameters in Children Receiving New-Generation Antidepressants.

Uchida M, Spencer AE, Kenworthy T, Chan J, Fitzgerald M, Rosales AM, Kagan E, Saunders A, Biederman J.

J Clin Psychopharmacol. 2017 Jun;37(3):359-362. doi: 10.1097/JCP.0000000000000683.

PMID:
28301398
11.

CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.

Kitaguchi T, Moriyama Y, Taniguchi T, Maeda S, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Miyamoto N.

J Pharmacol Toxicol Methods. 2017 May - Jun;85:73-81. doi: 10.1016/j.vascn.2017.02.001. Epub 2017 Feb 3.

PMID:
28163191
12.

High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death.

Ray WA, Chung CP, Murray KT, Hall K, Stein CM.

J Clin Psychiatry. 2017 Feb;78(2):190-195. doi: 10.4088/JCP.15m10324.

13.

Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management.

Tisdale JE.

Can Pharm J (Ott). 2016 May;149(3):139-52. doi: 10.1177/1715163516641136. Epub 2016 Apr 8. Review.

15.

Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial.

Detke HC, DelBello MP, Landry J, Usher RW.

J Am Acad Child Adolesc Psychiatry. 2015 Mar;54(3):217-24. doi: 10.1016/j.jaac.2014.12.012. Epub 2014 Dec 29.

16.

Central actions of serotonin and fluoxetine on the QT interval of the electrocardiogram in trout.

Kermorgant M, Lancien F, Mimassi N, Le Mével JC.

Comp Biochem Physiol C Toxicol Pharmacol. 2015 Jan;167:190-9.

PMID:
25445020
17.

Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports.

Kogut C, Crouse EB, Vieweg WV, Hasnain M, Baranchuk A, Digby GC, Koneru JN, Fernandez A, Deshmukh A, Hancox JC, Pandurangi AK.

Ther Adv Drug Saf. 2013 Oct;4(5):189-98. doi: 10.1177/2042098613492366.

18.

Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.

Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, Huffman JC.

J Clin Psychiatry. 2014 May;75(5):e441-9. doi: 10.4088/JCP.13r08672.

PMID:
24922496
19.

Clinically relevant interactions between newer antidepressants and second-generation antipsychotics.

Spina E, de Leon J.

Expert Opin Drug Metab Toxicol. 2014 May;10(5):721-46. doi: 10.1517/17425255.2014.885504. Epub 2014 Feb 5. Review.

PMID:
24494611
20.

Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study.

Girardin FR, Gex-Fabry M, Berney P, Shah D, Gaspoz JM, Dayer P.

Am J Psychiatry. 2013 Dec;170(12):1468-76. doi: 10.1176/appi.ajp.2013.12060860.

PMID:
24306340

Supplemental Content

Loading ...
Support Center